Aries Pharmaceuticals, Inc. Launches Eleview™ for use in Gastrointestinal Endoscopic Procedures
Novel Development in Submucosal Injection Agents Elevates Lesions to Facilitate Removal
SAN DIEGO – May 2nd, 2017 – Aries Pharmaceuticals, Inc. (Aries) today announced the launch and commercial availability of its first product, Eleview™, a novel, ready to use, submucosal injectable composition for use in the easy and safe endoscopic removal of polyps, adenomas, and early stage cancers, and other lesions in the gastrointestinal (GI) tract. Eleview was developed by Cosmo Pharmaceuticals, N.V. (SIX: COPN) (Cosmo). Aries is the sole distributor of Eleview in the United States.
Eleview offers important benefits for gastroenterologists. Upon injection, the product forms an immediate cushion of optimal shape, height, and duration. The inclusion of methylene blue, a contrast dye, improves visibility of the lesion. By providing an immediate and long-lasting cushion beneath the polyp and improving the visibility of the lesion, Eleview may help achieve a complete and safe removal of the lesion. When compared to saline, one of the most commonly used agents, Eleview has demonstrated better cushion-forming ability and a duration of lift of up to 45 minutes. As a ready to use, sterile, premixed composition, it is a convenient option for clinicians.
“Eleview offers a meaningful advancement designed specifically to help endoscopists improve their procedural capabilities for an easy and safe removal of polyps and lesions throughout the GI tract. This is important because effective removal of precancerous polyps in the colon is a critical component of colon cancer prevention.” noted David Kriesel, Executive Director of Medical Affairs. “Eleview’s duration of polyp lift, along with the contrast provided by methylene blue, helps physicians visualize the margins of the lesion, an important aspect of achieving a complete resection with a potential for lower risk of complications.”
“We are excited to announce the commercial availability of Eleview. Improving patient outcomes during colorectal cancer screening and surveillance colonoscopies is a key area of focus for our product portfolio,” Aries CEO Tom Joyce stated. “We look forward to supporting gastroenterologists in their mission to lower the incidence of colorectal cancer, which is the second most common yet preventable cancer in the United States. Our products are designed to make a significant difference within endoscopy and select gastroenterology conditions.”
As part of the company’s launch readiness efforts, Aries made a significant investment in the training of a U.S. based salesforce, including completion of the American Society for Gastrointestinal Endoscopy (ASGE) training for sales and marketing representatives. The training, which included both didactic learning as well as a hands-on component that introduced participants to basic and advanced endoscopic techniques, will enable Aries representatives to better partner with clinicians to support positive patient outcomes. Following successful completion of this training, all Aries participants receive ASGE Recognized Industry Associates (ARIA) designation.
Aries Presence at DDW
Aries will be at Digestive Disease Week (DDW) in Chicago, May 6-9th introducing Eleview™ to the gastroenterology community. The company will be exhibiting at Booth #2526 during DDW and hosting nine product breakout sessions throughout the conference. Cosmo, the parent company, plans to announce the outcome of Eleview’s clinical trial on May 8th. The results of the trial will be presented by Dr. Douglas Rex at DDW on May 8th.
Eleview submucosal injectable composition is intended for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early stage cancers or other gastrointestinal mucosal lesions, prior to excision with a snare or endoscopic device. Developed by Cosmo, Eleview has been 510(k) cleared by the FDA. Please see important safety information below and additional product information at EleviewUS.com. Eleview is available now for order at 888-ARIES-08.
Important Safety Information
WARNINGS AND PRECAUTIONS
- The safety of Eleview™ has not been established in pregnant or lactating women, or in children under 18 years of age.
- The endoscopist injecting Eleview™ must be experienced in the injection technique.
Patients with known sensitivity to any of the components contained in Eleview™.
- Rarely, local bleeding and/or inflammatory reaction could occur which may or may not be associated with Eleview™.
- Please see Instructions for Use for complete Important Safety Information.
About Aries Pharmaceuticals, Inc.
Aries Pharmaceuticals, Inc. (Aries) is a specialty pharmaceutical company commercializing best-in-class gastroenterology products for the United States market with a focus on products utilized in endoscopy and for the treatment of specific gastrointestinal diseases. The company’s initial portfolio of four products, three of which are still in development, are licensed from Cosmo Pharmaceuticals N.V. to Aries Limited. Aries Inc., is the US distribution arm of Aries Ltd., a wholly owned subsidiary of Cosmo Pharmaceuticals N.V. For further information on Aries, please visit the company’s website: www.ariespharma.com
Aries Pharmaceuticals, Inc.
Feinstein Kean Healthcare